| 13.78 -0.6 (-4.17%) | 11-17 13:00 | |||||||||||||
|
|
| Short term | |
|||
| Mid term | |
|||
| Targets | 6-month : | 21.67 | 1-year : | 25.97 |
| Resists | First : | 18.56 | Second : | 22.23 |
| Pivot price | 18.53 |
|||
| Supports | First : | 12.6 | Second : | 10.49 |
| MAs | MA(5) : | 16.93 |
MA(20) : | 18.57 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -1.2 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 18.1 |
D(3) : | 35.9 |
| RSI | RSI(14): 34.2 |
|||
| 52-week | High : | 38.4 | Low : | 12.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ VOGX ] has closed below the lower bollinger band by 7.4%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ VOGX ] is to continue within current trading range. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 16.75 - 16.85 | 16.85 - 16.92 |
| Low: | 12.42 - 12.53 | 12.53 - 12.6 |
| Close: | 14.23 - 14.4 | 14.4 - 14.53 |
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
Mon, 16 Nov 2026
Two firms report holding more than 5% of Vogenx (VOGX) on behalf of others. - Stock Titan
Mon, 16 Nov 2026
Options on 91,667 shares factor into a reported ownership stake in Vogenx (VOGX). - Stock Titan
Fri, 06 Nov 2026
Vogenx Reports $4.9 Million Quarterly Net Loss and $82.1 Million in Cash - TradingView
Fri, 06 Nov 2026
Vogenx (VOGX) Q3 Net Loss Widens to $4.9M - TradingView
Sun, 16 Aug 2026
Vogenx IPO Raises $81M for Trial in Metabolic Disease With No Approved Drugs - MedCity News
Thu, 13 Aug 2026
Vogenx Inc Common Stock (VOGX) News Headlines - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 15 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 4.7 (%) |
| Held by Institutions | 14 (%) |
| Shares Short | 38 (K) |
| Shares Short P.Month | 26 (K) |
| EPS | -0.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.35 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -62.28 |
| PEG Ratio | 0 |
| Price to Book value | -40.3 |
| Price to Sales | 0 |
| Price to Cash Flow | -236.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |